PHARMAC has made a decision to make changes to the funded brands of fluticasone and fluticasone with salmeterol metered dose inhalers (MDIs), which are used in the management of asthma and chronic obstructive pulmonary disease (COPD).
Decision to change the sole subsidised brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe
The funded brand of lidocaine [lignocaine] hydrochloride gel 2%, urethral syringe will change from Cathejell to Instillagel Lido.
Response to an Official Information Act request for communications between PHARMAC and Sanofi, on compassionate supply.
Response to a request for information for data on nivolumab and pembrolizumab Special Authorities, for July, August and September 2019.
Response to a request for information about communications around the Northland meningitis outbreak.
PHARMAC are pleased to announce changes to the funding of apomorphine hydrochloride, a medicine used to treat advanced Parkinson’s disease, through an agreement with Stada.
PHARMAC are seeking feedback on proposals to widen funded access to medicines in the blood, alimentary and immunosuppressant therapy areas.
Closes: 4pm Monday, 6 January 2020.
Decision to list medical devices in the interventional radiology category supplied by Becton Dickinson Limited
We are pleased to announce the approval of a listing agreement with Becton Dickinson Limited for the supply of interventional radiology medical devices to DHBs.
We are pleased to announce the approval of a listing agreement with O&M Halyard Australia Limited for listing of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 February 2020.
We are pleased to announce the approval of a listing agreement with New Zealand Medical & Scientific Limited for the supply of obstetrics and gynaecology products to DHBs.
PHARMAC is pleased to announce a decision to widen access to bortezomib for patients with multiple myeloma and amyloid light-chain (AL) amyloidosis in conjunction with a change of funded brand of bortezomib through PHARMAC’s annual tender process.
PHARMAC has made a decision to make changes to the funding of rituximab, including widening access and changing brands.
PHARMAC is pleased to announce a decision to fund two new cancer treatments and amend the contractual arrangements for one currently funded treatment through an agreement with AstraZeneca Pty Ltd.
Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year.
Response to a request for information about the MMR vaccine.
Response to a request for information about sex change treatments.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender dated 1 November 2018.
PHARMAC is seeking your feedback on the proposal to make changes to the funded brands of labetalol tablets, which are used in the treatment of hypertension in pregnancy.
Closes: 4pm, Monday 16 December 2019.
Response to an Official Information Act request for data on cefuroxime.
PHARMAC is seeking feedback on a proposal relating to how we fund discarded medicines (“wastage”) in community pharmacies.
Closes: 5 pm on Friday, 20 December 2019.